Alnylam Pharmaceuticals
ALNY
224.41
+0.47
+0.21%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
224.41
+0.47
+0.21%
Live - 5344 symbols - heartbeat 52s ago
· 2026-10-08 06:06
Pre-market
224.50
+0.04%
After-hours
224.41
0.00%
Overnight
224.32
-0.04%
- Market cap
- 30.03B
- P/E (TTM)i
- 39.10
- P/Bi
- 22.17
- EPSi
- 2.33
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ALNY?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 21 analysts
Buy
Avg price target
369.96 +64.9%
Price target rangecurrent 224.41
Low230.00
Avg369.96
High489.00
Buy 86%
Hold 14%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | Cantor Fitzgerald | -- | HOLD | 325.00 |
| 2026-09-30 | J.P. Morgan | -- | BUY | 369.00 |
| 2026-09-25 | Bernstein | -- | BUY | 376.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 455.00 |
| 2026-09-18 | Truist Financial | -- | BUY | -- |
| 2026-09-17 | Needham | -- | BUY | 357.00 |
| 2026-09-17 | BMO Capital | -- | BUY | 318.00 |
| 2026-09-16 | Bernstein | -- | BUY | 376.00 |
| 2026-09-11 | Morgan Stanley | -- | HOLD | 300.00 |
| 2026-09-02 | H.C. Wainwright | -- | BUY | 455.00 |
| 2026-09-01 | Barclays | -- | BUY | 450.00 |
| 2026-08-31 | Piper Sandler | -- | BUY | 489.00 |
| 2026-08-31 | BofA Securities | -- | BUY | 346.00 |
| 2026-08-31 | Truist Financial | -- | BUY | -- |
| 2026-08-31 | Evercore | -- | BUY | 325.20 |
| 2026-08-31 | Stifel | -- | BUY | 318.00 |
| 2026-08-31 | Citi | -- | BUY | 340.00 |
| 2026-08-30 | BofA Securities | -- | BUY | 346.00 |
| 2026-08-30 | BMO Capital | -- | BUY | 318.00 |
| 2026-08-28 | CCORF | -- | BUY | 429.00 |
| 2026-08-24 | Bernstein | -- | BUY | 376.00 |
| 2026-08-13 | Stifel | -- | BUY | 318.00 |
| 2026-08-05 | Evercore | -- | BUY | 325.20 |
| 2026-08-04 | Truist Financial | -- | BUY | 315.00 |
| 2026-08-04 | H.C. Wainwright | -- | BUY | 455.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Jefferies moved from Buy to Hold on 2026-03-15.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-15 | Jefferies | BUY → HOLD | 330.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | -- | ±10.10% | -28.31% (beat) |
| 2026/Q1 | 2026-04-30 | -- | ±7.83% | +2.76% (in line) |
| 2025/Q4 | 2026-02-12 | -- | ±6.44% | -4.28% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±10.17% | -6.65% (in line) |
| 2025/Q2 | 2025-07-31 | -- | ±8.25% | +15.43% (beat) |
| 2025/Q1 | 2025-05-01 | -- | ±9.13% | -3.08% (in line) |
| 2024/Q4 | 2025-02-13 | -- | ±7.08% | -0.40% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±8.42% | -5.29% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±7.79% | +13.12% (beat) |
| 2024/Q1 | 2024-05-02 | -- | ±8.84% | +0.23% (in line) |
| 2023/Q4 | 2024-02-15 | -- | ±5.44% | -10.19% (beat) |
| 2023/Q3 | 2023-11-02 | -- | ±7.41% | +2.89% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:06:04 · For reference only, not investment advice and not tailored to your situation.